THE ANGLO SCIENTIFIC EIS FUND

A GROWTH PORTFOLIO OF IDENTIFIED HOLDINGS WHICH IS OPEN FOR INVESTMENT ALL YEAR

The Anglo Scientific EIS Fund

Approved by Innvotec Limited which is Authorised and Regulated by the Financial Conduct Authority - FRN 122365
“INVESTING IN COMPANIES WITH TECHNOLOGIES THAT ADDRESS REAL AND GLOBAL NEEDS”
July 2017

Dear Investor,

Innvotec Limited “Innvotec” is once again pleased to provide this regular update on the performance of the Anglo Scientific EIS Funds since the inaugural Fund was launched in 2009.

After seven consecutive years of annual funds, in 2016 we changed the status of the Fund to “Evergreen” to meet the growing demand from investors for year-round access to EIS opportunities. The focus of the AS EIS Evergreen Fund remains the same as the previous annual funds – namely, making EIS Qualifying investments into a portfolio of identified, technology-based companies that have been founded by Anglo Scientific, or in which Anglo Scientific has had, or continues to have, an on-going role.

The AS EIS Fund is a growth fund - i.e. its key objectives are to give investors the opportunity to make a meaningful capital gain on their commitment, and at the same time, access the generous tax benefits available under the EIS rules.

The Fund invests in emerging, innovative companies that have the potential to be “best of breed” on a world stage and are assisted in their development by the highly-experienced team of entrepreneurs at Anglo Scientific. The combined expertise of Innvotec and Anglo Scientific ensures the portfolio companies have access to a wealth of support to help to minimise risk and take advantage of the very significant potential within each.

Regular and in-depth reporting to Investors on the progress of the Fund has always been, and will continue to be, high on Innvotec’s list of priorities. Investors in the Fund pay no initial charges and management fees are not levied until such time as the Fund has received its first returns. The Fund Manager’s Performance Fee is not payable until investors have received back 140% of their commitment so our interests in the AS EIS Fund are fully aligned with yours.

We hope that you find this update, the Information Memorandum and accompanying literature of interest. Please do not hesitate to contact us if you would like any further information or have any questions. We look forward to welcoming you as an investor.

Yours faithfully

John Marsden
Managing Director

---

THE ANGLO SCIENTIFIC EIS FUND

✓ 100% of money invested for tax relief purposes and no “hidden extras”.
✓ Timely receipt of EIS certificates.
✓ Performance fee hurdles are challenging and create an alignment of interests with investors.
✓ Client’s total commitment invested within 3 months.
TARGETED PORTFOLIO COMPANIES

One of the attractions of the AS EIS Fund is that it invests in a portfolio of companies, all of which are known to the Fund Manager and all of which benefit from the ongoing involvement of the Anglo Scientific team. This means that, prior to committing to the Fund, Investors will know with some certainty the companies that will be supported with their investment.

Every company targeted by the Fund is in the process of delivering truly ground breaking products and services that are applicable to a global audience. Some are more advanced on the path to product commercialisation than others, thus giving investors a portfolio with a spread of maturity and time to exit. With potentially strong competitive advantages, each company has the potential to deliver very high “exit” multiples and thus attractive returns.

As new companies are periodically added to the Portfolio, the mix of companies receiving investment is not fixed and may change over time.

If considered appropriate, the Fund will make strategic investments into companies not founded by Anglo Scientific, but where the Anglo Scientific team has been invited to use their know-how and expertise to strengthen the existing in-situ management.

Details of the current companies that are being targeted for investment from the AS EIS Fund follow over the next few pages.

The information on the companies in this document represents the best views of Anglo Scientific and Innvotec at the time of writing and are merely opinions. It is not something on which to base an investment decision.

Further information on the Anglo Scientific EIS Fund is available in the Information Memorandum, which is available on request.
New synthetic molecules with unique applications as life science research reagents, next generation diagnostics and therapeutics (each multi billion $ market segments).

Executive Summary

Apta Biosciences is bringing to market a pipeline of game changing healthcare products using “Seligos” - its proprietary, third generation affinity molecules. Apta is led by a team experienced in building life science companies from early stage to exit, and have realised $billions of value for investors.

Apta is a UK company with operations in Singapore. The Seligo platform was developed in Fujitsu over a period in excess of 10 years and with over $10m of investment prior to being spun off into Apta. Seligos combine the best attributes of synthetically engineered, “3D printable” oligonucleotide molecules with high-affinity protein-protein binding to enable targeted solutions for high value diagnostic, therapeutic and imaging applications.

Apta has a pipeline of healthcare products incorporating Seligos. The first product, a point of care diagnostic test for the Zika, Dengue and Chikungunya viruses, is planned for launch in 2017, unlocking a multi hundred million $ market opportunity and delivering a significant global health solution. Other product lines are scheduled to follow, including a test that could lead to improved pregnancy outcomes in the field of Women’s Health.

Further Details

Web:
www.aptabiosciences.com

Launch Date (date of incorporation):
August 2013

Size of the market the company is operating in:
$10s of billions

Current user base:
Products in development with first launch expected in 2017

Customers:
Research groups
Diagnostic corporates
Therapeutic/pharma corporates
Reagent suppliers

Distribution strategy:
Direct and channel partners

Press - recent articles:
**Microtest DX**

An innovative provider of allergy testing and management bringing benefits to both physicians and sufferers.

**Executive Summary**

The World Allergy Organisation estimates that 30% - 40% of the world's population are affected by one or more allergies. Existing allergy tests can take weeks to identify the most troublesome allergens for any given patient and are subject to false positives. Allergy sufferers are often asked to make tough lifestyle choices based on incomplete or inaccurate diagnosis. Also, most existing allergy tests are expensive and some common procedures (e.g. skin pricking) are quite unpleasant for patients, especially children.

Instead of testing allergens against IgE one at a time, Microtest has developed a microarray in which multiple allergens are tested simultaneously in a panel using a few drops of blood from a single patient sample. The Microtest testing process allows doctors and clinicians to shorten and improve the quality of the allergy diagnostic process as well as providing guidance for physicians working with allergy patients in the fields of medical, immunological and dietary management. The process is based on a proprietary blood test that determines the scope and degree of sensitisation to the most common allergens.

---

**Further Details**

- **Web:**
  [www.microtestdx.com](http://www.microtestdx.com)

- **Launch Date (date of incorporation):**
  December 2009

- **Size of the market the company is operating in:**
  $ billions

- **Current user base:**
  Current revenues derive from allergy testing services from a laboratory based in New Jersey, USA.

- **Customers:**
  Other testing laboratories
  Immunoassay companies looking for purified proteins

- **Distribution strategy:**
  A combination of distributors, Microtest's own labs and third party laboratories.

- **Press - recent articles:**
  September 22, 2016, High prevalence of allergic sensitisation in pediatric asthma.

Phasor is introducing a major breakthrough in satellite communications: the world’s first electronically steerable antennas to enable broadband communications to vehicles on the move such as aeroplanes, trains, boats, UAV’s and others.

Phasor is engaged with many of the world’s biggest communications companies (e.g. Intelsat, Gogo, Thales, Harris Caprock), and has signed a variety of agreements that ensure rapid deployment of its technology. Collectively they have committed to buy over $100m of Phasor antennas to maintain those exclusivities over the next 3-5 years.

Executive Summary

Mobile broadband presents a huge opportunity. Cisco estimates that demand in 2020 will be eight times greater than it was in 2015. To meet it, billions of dollars are being spent on new and better communications satellites. While demand for mobile broadband is surging, mobile broadband communications services are constrained by current satellite antennas technologies. Broadband communication antennas are the “gating-factor” that when successfully addressed, will allow these services to exist and thrive.

Phasor’s novel antenna enables satellites to be tracked electronically with no moving parts. This allows the antenna to be so thin that it can be flush against the surface of the vehicle itself.

Today Phasor is at an advanced stage in development, transforming its technology to market-ready products. Phasor’s breakthrough antennas replace traditional mechanical, convex satellite-dishes linked to gimbal motors which have been a limiting factor in the growth of satellite communications, thus unlocking explosive growth in commercial mobile broadband everywhere - in flight, at-sea or while en route over land.

Further Details

Web:
www.phasorsolutions.com

Launch Date (date of incorporation):
2005

Size of the market the company is operating in:
$ billions

Current user base:
Communication integrators to aeroplanes, boats, trains and military vehicles. The company has announced commercial agreements with OmniAccess for superyachts, Harris Caprock (now Speedcast) for cruises, Intelsat for business jets, Gogo for commercial aircraft and Thales Alenia Space for defence applications.

Customers:
Large satellite companies
Communication integrators to aeroplanes, boats and trains.

Distribution strategy:
Partner with communication integrators in different verticals of communications to moving vehicles

Press - recent articles:


Radio Physics is developing its technology to detect concealed threats such as bombs and guns (even 3-D printed ones) faster, cheaper, more efficiently and more reliably than current solutions, thus enabling it to plug key gaps in the current layers of security.

Executive Summary

Radio Physics’ technology enables rapid, unobtrusive screening of people for concealed weapons, including guns and suicide bombs, without the need to funnel people through fixed portals or gateways.

The technology does not “see” through clothing in the traditional sense, but it can accurately identify people that are carrying concealed objects that might pose a threat, thus enabling security services to deal with potentially dangerous situations quickly and efficiently.

The RP detection system is called MiRTLE (Millimeter wave Radar Threat Level Evaluation). MiRTLE detects bombs and guns, including 3D-printed guns, at a range of up to 30 metres. The current MiRTLE product is mounted on a tripod, however a future version will be handheld. Both versions are portable and battery-operated, and can be linked to CCTV and other networks so that continuous monitoring by human operators is not required. MiRTLE thus provides an additional layer of security by extending the boundaries of detection beyond the conventional metal detector portals installed in airports and other defined locations.

Users will be able to deploy RPS products into existing layers of security and plug “key” gaps in the defences of citizens and security personnel the world over. Users will find the system both easy to use and capable of being retrofitted to the current layered approach to security.

Shareholders will benefit from “game changing” products that are likely to be widely adopted by security services, both commercial and governmental, world-wide.

The company has already received a number of orders, with significant further interest from security agencies in several countries.

Further Details

Web:
www.rpssys.com

Launch Date (date of incorporation):
2009

Size of the market the company is operating in:
$4 billion growing 50% per annum

Current user base
Initial purchase orders secured.

Customers:
Network and security channel partners that deliver systems to multiple agencies in a focused number of geographies.

Distribution strategy:
Channel Partners

Press - recent articles:
Developing tools to help police and other security teams identify, locate and track criminals and missing people. Essentially SeeQuestor aims to “Find People in Video”.

Executive Summary

SeeQuestor aims to tilt the playing-field in favour of those working to reduce crime and save lives by helping police and security teams search through vast amounts of CCTV data at speed, to identify and disrupt criminal activity or to find missing people.

Video data is a large untapped resource. 1.4 trillion hours of CCTV was generated worldwide last year (200,000 hours of footage for the London Riots alone in 2012). But only a fraction of 1% is ever looked at because current practice involves 1 hour of “eyeballing” by a CCTV analyst for each hour of data. So whilst video is a terrific resource to protect the innocent, help the police find missing people and solve crimes, using it productively poses severe challenges.

SeeQuestor is seeking to change all this with its (proprietary) “game changing” video analytics and data management system. The aim being to revolutionise the way police and security personnel deal with video and thus help to solve more crimes and save more lives.

SeeQuestor is working with some of the largest users of video in the UK (groups such as SO15, the Met’s Homicide Command and the British Transport Police to name a few) to develop and trial the product. Customers are now paying to use the system to interrogate large amounts of video in high profile cases from around the world. SeeQuestor’s Format Conversion Service, which enables video in any format to be converted to a readable standard, is also generating much interest.

The team combines leading national security expertise, a former senior exec from Cisco, IBM & Thalys, world leading research and a track record of successful software entrepreneurship.

Further Details

Web: www.seequestor.com

Launch Date (date of incorporation): June 2014

Size of the market the company is operating in: Valued at $7.5 billion in 2012 by Homeland Security Research and growing.

Current user base: Engaged with potential teacher customers including the Metropolitan Police & the British Transport Police. System trials have been undertaken with UK Counter-Terrorism Command under the Home Office Video Analytics for Law Enforcement (VALE) programme. The system has been used with significant success on high profile cases from Australia and the US, and others are underway.

Customers: Initial customers include Queensland Police, Suffolk Police and Phoenix Police.

Distribution strategy: Routes to market include direct system sales, SaaS and web services - a “pay-as-you-go” service which is generating much interest. In secondary markets, agents and distributors are being appointed.


www.seequestor.com/assets/doc/SeeQuestor%20Queensland%20news%20release%20Nov%202019%20FINAL%20KH.pdf
THE ANGLO SCIENTIFIC EIS FUND

TARGETED - PORTFOLIO COMPANIES

Tharos

The delivery of improved equine health and performance through optimal digestion.

Executive Summary

Tharos (Ancient Greek for “guts and courage”) was formed in 2015 and aims to introduce a range of equine dietary and medicinal products, commencing with a food supplement that bestows measurable improvements in a horse’s digestion, performance and condition. The first product, “EquiNectar” has been successfully trialled at a leading race yard for three years and is now being prepared for a soft launch in 2017.

Digestive upset, connected to colonic malfermentation, is a common and detrimental factor in modern equine husbandry the world over. EquiNectar has been shown to improve disordered and inefficient fermentation in the horse gut by bettering the digestion of carbohydrates and lowering the level of acidity in the cecum and large bowel. EquiNectar thus restores and maintains the horse’s microbiome to ensure a healthy gut and balances the digestive biochemistry (by lowering acetate and reducing endotoxicity). This improves performance and condition through better conversion of feed to energy.

EquiNectar will undergo a soft launch to 20 yards in 2017 and is expected to be commercially launched as an equine food supplement in 2018 to the UK market. The directors believe that the benefits of EquiNectar on the equine gut are highly likely to improve the recovery prospects for horses prone to, or suffering from, colic and laminitis - both debilitating and potentially fatal conditions affecting a significant proportion of the worldwide equine population.

With its scientifically validated and patent protected nutritional technology, Tharos is targeting opportunities in the annual global horse healthcare market, which is estimated between £24bn and £26bn.

Tharos comprises, unconventionally, experts hailing from both the medical and veterinary fields. They have spent their professional lives studying toxicology, metabolomics, gastro-intestinal physiology, and acute and chronic gastro-intestinal illness.

Further Details

Web:
www.tharos.co.uk

Launch Date (date of incorporation):
December 2015

Size of the market the company is operating in:
Annual global horse healthcare market estimated at £26bn

Current user base:
Soft launch to selected yards in 2017.

Customers:
Racing and other professional yards, and individuals.

Distribution strategy:
B2B bulk sales to professional yards, e-commerce to individuals.

Press - recent articles:
recent articles: www.thehorse.com/articles/33228/digestion-in-the-horse
THE ANGLO SCIENTIFIC EIS FUND - A PROVEN STRATEGY

Innvotec and Anglo Scientific have now been collaborating on the AS EIS Funds since 2009. Over that period, in excess of 70 separate investments have been made in a growing portfolio of companies founded and led by Anglo Scientific.

Anglo Scientific builds businesses that are addressing global markets with products based on proprietary, patent-protected technology. Bringing their wealth of entrepreneurial talent and significant business and commercial experience to the table, the companies are guided through their early growth stages by Anglo Scientific and financed by a combination of angel investors, institutions and the AS EIS Funds.

With a programme of periodically starting new companies, the portfolio is growing and offers investors a spread of maturities from start up to those starting to build revenues in their markets. The close collaboration of Innvotec as the Fund Manager with the Anglo Scientific team provides the Fund with a unique structure through which private investors can share in the success of this portfolio of exciting, high growth businesses.

The AS EIS Fund is unashamedly a “growth” fund. Its aim is to provide investors with significant capital gains and at the same time, take advantage of the generous tax benefits available under the EIS scheme. The first “exit” from a portfolio company was completed recently and, before taking account of any tax benefits, will provide investors with a return of up to 5x. Other companies in the portfolio are now starting to mature and it is likely that opportunities for further exits will arise in the near future.

The graphics on the following charts provide an overview of the performance of the Funds since inception in 2009, up to the end of 2016 and currently show an average uplift on cost of 28% based on BVCA and industry standard valuation criteria. This performance compares favourably with their peer group of other EIS funds as well as with the FTSE 100. We are confident that there is a very real prospect of considerably higher growth yet to come.
Total Percentage Returns are based on 30th June 2017 FTSE Index and each fund’s uplift is based on value per the latest investment round against the cost of investment.
Anglo Scientific EIS Funds - Compound Annual Growth Rates (CAGRs)

% Returns are calculated on price per share paid by subsequent third party investors compared to the cost of assembling the portfolio.
Current Portfolio Companies for all AS EIS Funds
Amount Raised vs Valuation

<table>
<thead>
<tr>
<th>Companies</th>
<th>Amount Raised</th>
<th>Valuation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apta Biosciences</td>
<td>£5m</td>
<td>£45m</td>
</tr>
<tr>
<td>Microtest DX</td>
<td>£10m</td>
<td>£30m</td>
</tr>
<tr>
<td>Phasor</td>
<td>£25m</td>
<td>£40m</td>
</tr>
<tr>
<td>Radio Physics</td>
<td>£35m</td>
<td>£25m</td>
</tr>
<tr>
<td>SeeQuestor</td>
<td>£5m</td>
<td>£15m</td>
</tr>
<tr>
<td>Solus</td>
<td>£0</td>
<td>£5m</td>
</tr>
<tr>
<td>Tharos</td>
<td>£0</td>
<td>£0</td>
</tr>
</tbody>
</table>
“A UNIQUE APPROACH TO INVESTMENT IN AN EIS FUND DEDICATED TO GROWTH”
THE ANGLO SCIENTIFIC EIS FUND

A GROWTH PORTFOLIO OF IDENTIFIED HOLDINGS WHICH IS OPEN FOR INVESTMENT ALL YEAR

Further Information

If any further information relating to the Fund is required please contact the Fund Manager, Innvotec Limited.

Fund Manager
Innvotec Limited

Corporate, Marketing & Sales
Painters Hall
9 Little Trinity Lane
London
EC4V 2AD

t:+44 (0) 207 630 6990
e: info@innvotec.co.uk

Admin & Client Support
Suite 310
Business Design Centre
52 Upper Street
London
N1 0QH

t:+44 (0) 207 630 6990
e: info@innvotec.co.uk

www.innvotec.co.uk

Anglo Scientific EIS Fund specific
e: angloeis@innvotec.co.uk

Strategic Partner
Anglo Scientific Limited
The Royal Institution of Great Britain
21 Albemarle Street
London
W1S 4BS UK

www.angloscientific.com
t:+44 (0) 1531 651 230
e: info@angloscientific.com

Legal Adviser
Bircham Dyson Bell LLP
50 Broadway
London
SW1H 0BL

wwwbdb-law.co.uk
t:+44 (0) 20 7227 7000
e: enquiries@bdb-law.co.uk

Marketing Adviser
Palladium Results Ltd
4 The Willows
Mill Farm Courtyard
Beachampton
Milton Keynes
MK19 6DS

www.palladiumsolutions.com
t:+44 (0) 1908 566800
e: anglo@palladiumsolutions.com